Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes

Table 1 Characteristics of Included Studies

Ref.	Country	Study period (year)	Study design	Sample size (ropeginterferon; standard)	Male sex, % (ropeginterferon; standard)	Outcomes reported
Barbui et al[20], 2023	Italy	2	RCT	64; 63	73.4 (47/64); 61.9 (39/63)	CHR, molecular response, AEs leading to discontinuation, thrombotic events, change in JAK2V617F allele burden, number of phlebotomies per patient-year
Barbui et al[19], 2024	Italy	5	RCT	64; 63	73.4 (47/64); 61.9 (39/63)	CHR, AEs leading to discontinuation, thrombotic events, number of phlebotomies per patient-year
Gisslinger et al[22], 2020 (P)	Europe	3.5	RCT	127; 127	46.5 (59/127); 47.2 (60/127)	CHR, molecular response, AEs leading to discontinuation, thrombotic events, change in JAK2V617F allele burden
Gisslinger et al[22], 2020 (C)	Europe	5	RCT	95; 76	50.5 (48/95); 52.6 (40/76)	CHR, molecular response, thrombotic events, change in JAK2V617F allele burden
Kiladjian et al[18], 2022 (P)	Europe	5	RCT	127; 127	46.5 (59/127); 47.2 (60/127)	CHR, molecular response, AEs leading to discontinuation, thrombotic events, change in JAK2V617F allele burden

RCT: Randomized controlled trial; CHR: Complete hematological response; AEs: Adverse events; P: PROUD-PV phase; C: CONTINUATION-PV phase.

Table 2 Baseline patient characteristics across included studies

Ref.	Age (mean ± SD) ropeginterferon; standard	Sex (male/female) ropeginterferon; standard	Hematocrit (mean ± SD, %) ropeginterferon; standard	Platelet count (mean ± SD, × 109; L) ropeginterferon; standard	Leucocyte count (mean ± SD, × 109; L) ropeginterferon; standard	Spleen size (mean ± SD, cm) ropeginterferon; standard	Splenomegaly (%) ropeginterferon; standard
Barbui et al[20], 2023	50.8 ± 7.4; 49.8 ± 10.4	47/17; 39/24	43.9 ± 2.0; 44.0 ± 2.7	620 ± 188; 640 ± 260	10.9 ± 3.9; 10.4 ± 4.9	2.3 ± 0.8; 3.2 ± 2.3	33.3; 28.6
Barbui et al[19], 2024	50.8 ± 7.4; 49.8 ± 10.4	47/17; 39/24	43.9 ± 2.0; 44.0 ± 2.7	620 ± 188; 640 ± 260	10.9 ± 3.9; 10.4 ± 4.9	2.3 ± 0.8; 3.2 ± 2.3	33.3; 28.6
Gisslinger et al[22], 2020 (P)	59.3 ± 10.5; 58.3 ± 14.3	59/68; 60/67	47.5 ± 5.3; 48.3 ± 5.3	502 ± 241; 482 ± 253	10.7 ± 4.1; 11.0 ± 5.0	13.0 ± 3.0; 13.2 ± 2.8	9.0; 12.0
Gisslinger et al[22], 2020 (C)	57.3 ± 10.5; 57.8 ± 12.5	48/47; 40/36	48.0 ± 5.7; 49.7 ± 5.2	513 ± 264; 486 ± 264	11.2 ± 5.0; 11.7 ± 4.8	13.3 ± 2.6; 13.2 ± 3.2	7.0; 11.0
Kiladjian et al[18], 2022 (P)	60.0 ± 10.4; 60.0 ± 14.1	59/68; 60/67	47.1 ± 5.3; 48.0 ± 5.9	485 ± 238; 452 ± 250	10.6 ± 4.0; 10.5 ± 4.9	15.3 ± 6.7; 15.5 ± 10.7	9.4; 11.8

P: PROUD-PV phase; C: CONTINUATION-PV phase.